Skip to main content
Open Access Publications from the University of California
search
Menu
About eScholarship
Main Menu
About eScholarship
eScholarship Repository
eScholarship Publishing
Site policies
Terms of Use and Copyright Information
Privacy statement
Campus Sites
Main Menu
UC Berkeley
UC Davis
UC Irvine
UCLA
UC Merced
UC Riverside
UC San Diego
UCSF
UC Santa Barbara
UC Santa Cruz
UC Office of the President
Lawrence Berkeley National Laboratory
UC Agriculture & Natural Resources
UC Open Access Policies
eScholarship Publishing
Scholarly Works (2 results)
Article
Peer Reviewed
Progress in prostate cancer imaging
Gulley, James L
;
Emberton, Mark
;
Kurhanewicz, John
;
Choyke, Peter
UC San Francisco Previously Published Works
(2012)
There are multiple new technologies being developed for imaging of advanced prostate cancer. This Seminar article highlights several of these emerging modalities that were discussed at the Society of Urologic Oncology annual meeting in Bethesda, MD.
Article
Peer Reviewed
Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus
Tan, Wei Phin
;
Rastinehad, Ardeshir R
;
Klotz, Laurence
;
Carroll, Peter R
;
Emberton, Mark
;
Feller, John F
;
George, Arvin K
;
Gill, Inderbir S
;
Gupta, Rajan T
;
Katz, Aaron E
;
Lebastchi, Amir H
;
Marks, Leonard S
;
Marra, Giancarlo
;
Pinto, Peter A
;
Song, Daniel Y
;
Sidana, Abhinav
;
Ward, John F
;
Sanchez-Salas, Rafael
;
de la Rosette, Jean
;
Polascik, Thomas J
;
Authors, Focal Therapy Group
;
Katz, Aaron
;
Sidana, Abhinav
;
Aminsharifi, Alireza
;
Lebastchi, Amir
;
Abreu, Andre
;
Villers, Arnauld
;
Schulman, Ariel
;
Rastinehad, Ardeshir
;
George, Arvin
;
Oto, Aytekin
;
Turkbey, Baris
;
Malavaud, Bernard
;
Muller, Berrend
;
Moore, Caroline
;
Eberli, Daniel
;
Margolis, Daniel
;
Song, Daniel
;
Lomas, Derek
;
Marra, Giancarlo
;
Orabi, Hazem
;
Lepor, Herbert
;
Tan, Hui Meng
;
Gill, Inderbir S
;
Jambor, Ivan
;
de la Rosette, Jean
;
Grummet, Jeremy
;
Feller, John
;
Ward, John
;
Colemen, Jonathan
;
Gregg, Justin
;
Tay, Kae Jack
;
Klotz, Laurence
;
Marks, Leonard
;
Deane, Leslie
;
Laguna, M Pilar
;
Emberton, Mark
;
Kimura, Masaki
;
Tsivian, Matvey
;
Gorin, Michael
;
Siddiqui, Minhaj
;
Ukimura, Osamu
;
Gontero, Paolo
;
Carroll, Peter
;
Pinto, Peter
;
Mozer, Pierre
;
Sanchez-Salas, Rafael
;
Gupta, Rajan T
;
Arcot, Ro
;
Taneja, Samir
;
Ghai, Sangeet
;
Crouzet, Sebastian
;
Mehralivand, Sherif
;
Joniau, Steven
;
Shoji, Sunao
;
Shiraishi, Takumi
;
Polascik, Thomas
;
Shin, Toshitaka
;
Lindnet, Uri
;
Tammisetti, Varaha
;
Tan, Wei Phin
;
van den Bos, Willemien
;
Matsuoka, Yoh
UC San Francisco Previously Published Works
(2021)
Background
With the advancement of imaging technology, focal therapy (FT) has been gaining acceptance for the treatment of select patients with localized prostate cancer (CaP). We aim to provide details of a formal physician consensus on the utilization of FT for patients with CaP who are discontinuing active surveillance (AS).
Methods
A 3-stage Delphi consensus on CaP and FT was conducted. Consensus was defined as agreement by ≥80% of physicians. An in-person meeting was attended by 17 panelists to formulate the consensus statement.
Results
Fifty-six respondents participated in this interdisciplinary consensus study (82% urologist, 16% radiologist, 2% radiation oncology). The participants confirmed that there is a role for FT in men discontinuing AS (48% strongly agree, 39% agree). The benefit of FT over radical therapy for men coming off AS is: less invasive (91%), has a greater likelihood to preserve erectile function (91%), has a greater likelihood to preserve urinary continence (91%), has fewer side effects (86%), and has early recovery post-treatment (80%). Patients will need to undergo mpMRI of the prostate and/or a saturation biopsy to determine if they are potential candidates for FT. Our limitations include respondent's biases and that the participants of this consensus may not represent the larger medical community.
Conclusions
FT can be offered to men coming off AS between the age of 60 to 80 with grade group 2 localized cancer. This consensus from a multidisciplinary, multi-institutional, international expert panel provides a contemporary insight utilizing FT for CaP in select patients who are discontinuing AS.
Top